EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Assessment of Tetrahydrocurcuminoids From Turmeric ( Curcuma ⁠longa L.) as a Novel Food for Use in Food Supplements (RP2124)

FSA Research and Evidence · 29.04.2026

DOI: 10.46756/001c.160332 ↗

Kurz gefasst

Fachartikel in der Zeitschrift FSA Research and Evidence, online erschienen am 29.04.2026. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sabinsa Europe GmbH, Germany (“the applicant”) submitted a novel food application for the authorisation of tetrahydrocurcuminoids (THCus; trade name Curcumin C3 Reduct®) as a novel food to each nation of Great Britain, in September 2023. This new application is for THCus for use in a food supplements (as defined in The Food Supplements (England) Regulations (2003) and associated legislation in the nations of GB), for those 18 years of age or older only , excluding pregnant and lactating women, at a maximum daily dose of 140 mg. THCus are manufactured by hydrogenating curcuminoids from the rhizomes of the Curcuma longa (turmeric) plant, which are then dried to yield the novel food as a purified powder. The turmeric rhizome and extract of the rhizome containing curcuminoids are not classified as a novel food when used in food supplements. THCus obtained by hydrogenating the curcuminoids extracted from turmeric are considered as a novel food, and therefore requires authorisation before they are placed on the GB market. This novel food had its application for authorisation assessed by the European Food Safety Authority (EFSA) which was published with a positive opinion of safety in October 2021. The Food Standards Agency (FSA) and Food Standards Scotland (FSS) have reviewed the information available, including the EFSA opinion, and concluded that the proposed conditions of use are not expected to pose a safety concern for the general population. However, based on the conclusions of the Committee on Toxicity (COT), idiosyncratic hepatotoxicity IDH cannot be completely ruled out for certain susceptible individuals, even at intakes below 140 mg per day. The anticipated intake levels and proposed use in food supplements was not considered to be nutritionally disadvantageous. This safety assessment represents the opinion of the FSA and FSS.

Zitieren

APA

(2026). Assessment of Tetrahydrocurcuminoids From Turmeric ( Curcuma ⁠longa L.) as a Novel Food for Use in Food Supplements (RP2124). FSA Research and Evidence. https://doi.org/10.46756/001c.160332

Vancouver

Assessment of Tetrahydrocurcuminoids From Turmeric ( Curcuma ⁠longa L.) as a Novel Food for Use in Food Supplements (RP2124). FSA Research and Evidence. 2026. doi:10.46756/001c.160332

BibTeX
@article{euvimed2026,
  title = {Assessment of Tetrahydrocurcuminoids From Turmeric ( Curcuma ⁠longa L.) as a Novel Food for Use in Food Supplements (RP2124)},
  journal = {FSA Research and Evidence},
  year = {2026},
  doi = {10.46756/001c.160332}
}
Kostenlos starten →